What is on the Burna AI roadmap?

Three lanes. Same engine, new lane (therapeutic adjacency that preserves the CTCAE substrate): gene therapy long-term follow-up under the FDA 15-year mandate; cardio-oncology; rare disease oncology indications; expanded postmarket pharmacovigilance for approved oncology drugs. Same engine, new geography: EU and UK deployment, with EMA E2B(R3) submission support. New engine, new market (separate engine, deliberate sequencing): psychiatric AE grading, which has its own grading framework. Features deliberately not on the roadmap: dose modification AI (FDA SaMD risk, killed), RECIST and tumor response (breaks same-engine logic, killed), patient recruitment and matching (crowded, distinct buyer).